Posts tagged #pharmacy

Breastfeeding Pharmacy: Antibiotics

Expert Commentary

Emergency Medicine practitioners may be quick to recommend patients to “pump and dump” when on antibiotics, but this can have downstream detrimental effects on the baby and on the mother. With the numerous indications for antibiotics, including some dealing with breastfeeding itself, it is imperative that EM providers recognize that most antibiotics are considered safe.

Most beta-lactam antibiotics are considered safe in breastfeeding women and can be used to treat many infections. Depending on the type of infection, anaerobic coverage may be warranted. Case reports have documented the potential for metronidazole to cause Candida infections and diarrhea in the infant. Clindamycin has the highest potential to cause GI issues in the breastfed infant. If these medications are indicated, it is best to have a risk-benefit discussion with the patient about the best option.

Tetracyclines have historically been feared in breastfeeding mothers due to the potential for bone deposition and staining of the dental enamel. As more literature has reviewed their safety, tetracyclines are considered safe for short term use, but limit courses to fewer than 21 days. Tetracycline absorption is also inhibited by calcium, which is contained in breast milk, so the amount actually absorbed by the infant should be low.

My favorite database to find information on medications in lactation is LactMed, a database funded by the NIH. Always the safest bet is to check this database before prescribing a medication to a lactating patient.

Kelsea Caruso, PharmD

Clinical Pharmacist

Department of Emergency Medicine

Northwestern Memorial Hospital

How To Cite This Post:

[Peer-Reviewed, Web Publication] Premer-Barragan, C. Payne, A. (2023, Jul 25). Breastfeeding Pharmacy Antibiotics. [NUEM Blog. Expert Commentary by Caruso, K]. Retrieved from http://www.nuemblog.com/blog/breastfeeding-pharm-antibiotics

Neuroleptic Malignant Syndrome

Expert Commentary

This is an awesome, focused review of neuroleptic malignant syndrome (NMS). NMS is hard to diagnose because it's rare. There is no gold standard with respect to its definition, and it requires a medication history (which we typically don't do very well in the emergency department). A tricky cause of NMS is the removal of a dopamine agonist. For this reason, carbidopa/levodopa should never be discontinued during hospital admission - or ED boarding. [1]

Supportive care is more important than antidotal therapy during NMS management. The most acute cause of death from NMS is hyperthermia, which is induced both by D2 receptor antagonism leading to rigidity and impaired thermoregulation from the striatum and hypothalamus. Any life-threatening hyperthermia should be treated immediately with an ice bath.[2] Rigidity will lead to rhabdomyolysis with subsequent hyperkalemia and myoglobin-induced renal failure. Therefore, fluid resuscitation and maintenance are important. Profound immobility can precipitate DVT, so anticoagulation may be necessary.

In terms of pharmacotherapy, benzodiazepines are universally used. Dantrolene inhibits calcium-mediated muscle contraction to reduce muscle rigidity. However, it doesn't address the underlying central D2 antagonism, and its efficacy has only been shown in case reports. Bromocriptine acts more centrally as a dopamine agonist but should be used cautiously in patients with psychiatric diseases as it may exacerbate psychosis. Overall, benzodiazepine use and supportive care should get you through most cases of NMS, though additional therapies may be necessary in severe cases.

References

1. Institute for Safe Medication Practices. Delayed Administration and Contraindicated Drugs Place Hospitalized Parkinson’s Disease Patients at Risk. 12 March 2015. Accessed February 11, 2022.

2. Juurlink JN. Antipsychotics. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. eds. Goldfrank's Toxicologic Emergencies, 11e. Page 1037-1039. McGraw Hill; 2019. Accessed February 11, 2022.

Zachary Schmitz, MD

Toxicology Fellow

Ronald O. Perelman Department of Emergency Medicine

NYU Langone Health

How To Cite This Post:

[Peer-Reviewed, Web Publication] Leibowitz, M. Wleklinski, N. (2022, May 9). Neuroleptic Malignant Syndrome. [NUEM Blog. Expert Commentary by Schmitz, Z]. Retrieved from http://www.nuemblog.com/blog/neuroleptic-malignant-syndrome.